The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Harri Alenius; Hanna Sinkko; Lucas Moitinho-Silva; Elke Rodriguez; Conor Broderick; Helen Alexander; Matthias Reiger; Mathis Hjort Hjelmsø; Nanna Fyhrquist; Peter Olah; Paul Bryce; Catherine Smith; Frits Koning; Kilian Eyerich; Dario Greco; Ellen H. van den Bogaard; Avidan U. Neumann; Claudia Traidl-Hoffmann; Bernhard Homey; Carsten Flohr; Klaus Bønnelykke; Jakob Stokholm; Stephan Weidinger

doi:10.1111/exd.14446

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Harri Alenius, Hanna Sinkko, Lucas Moitinho-Silva, Elke Rodriguez, Conor Broderick, Helen Alexander, Matthias Reiger, Mathis Hjort Hjelmsø, Nanna Fyhrquist, Peter Olah, Paul Bryce, Catherine Smith, Frits Koning, Kilian Eyerich, Dario Greco, Ellen H. van den Bogaard, Avidan U. Neumann, Claudia Traidl-Hoffmann, Bernhard Homey, Carsten FlohrKlaus Bønnelykke, Jakob Stokholm, Stephan Weidinger

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.

Original language	English
Pages (from-to)	1517-1531
Number of pages	15
Journal	Experimental Dermatology
Volume	30
Issue number	10
DOIs	https://doi.org/10.1111/exd.14446
State	Published - Oct 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.

Funding

The research has received funding from the FP7 (MAARS?Grant 261366) and IMI2 (BIOMAP?Grant 821511). The research has received funding from the FP7 (MAARS—Grant 261366) and IMI2 (BIOMAP—Grant 821511). Funding agencies have widely embraced collaborative funding models for research consortia such as the large‐scale Innovative Medicines Initiative (IMI). IMI is a public‐private partnership that aims to improve health by speeding up the development of innovative medicines, particularly in areas where there is an unmet medical and/or social need. IMI is the world's biggest public‐private partnership in the life sciences. The partnership includes the European Commission (EC) (representing the EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) (representing pharmaceutical industry partners), and is supported by these two parties. Industry partners contribute to the projects in a variety of ways, including bringing in‐kind consortium capacity and knowhow, while the EC matches the overall value of these contributions to fund activities provided by academia, small‐ to medium‐sized enterprises, and other non‐industry groups. Since 2006, the IMI has funded more than 120 projects with more than 1.5 billion € of EU funding focused on major diseases affecting European citizens. 178

Funders	Funder number
IMI2	BIOMAP?Grant 821511
Seventh Framework Programme	261366, 821511
European Federation of Pharmaceutical Industries and Associations
European Commission

Keywords

atopic dermatitis
biomarkers
microbiome
psoriasis

Access to Document

10.1111/exd.14446

Cite this

Alenius, H., Sinkko, H., Moitinho-Silva, L., Rodriguez, E., Broderick, C., Alexander, H., Reiger, M., Hjelmsø, M. H., Fyhrquist, N., Olah, P., Bryce, P., Smith, C., Koning, F., Eyerich, K., Greco, D., van den Bogaard, E. H., Neumann, A. U., Traidl-Hoffmann, C., Homey, B., ... Weidinger, S. (2021). The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases. Experimental Dermatology, 30(10), 1517-1531. https://doi.org/10.1111/exd.14446

@article{16aadeb47cc542dc84ae229973a2c4aa,

title = "The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases",

abstract = "The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.",

keywords = "atopic dermatitis, biomarkers, microbiome, psoriasis",

author = "Harri Alenius and Hanna Sinkko and Lucas Moitinho-Silva and Elke Rodriguez and Conor Broderick and Helen Alexander and Matthias Reiger and Hjelms{\o}, {Mathis Hjort} and Nanna Fyhrquist and Peter Olah and Paul Bryce and Catherine Smith and Frits Koning and Kilian Eyerich and Dario Greco and {van den Bogaard}, {Ellen H.} and Neumann, {Avidan U.} and Claudia Traidl-Hoffmann and Bernhard Homey and Carsten Flohr and Klaus B{\o}nnelykke and Jakob Stokholm and Stephan Weidinger",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.",

year = "2021",

month = oct,

doi = "10.1111/exd.14446",

language = "אנגלית",

volume = "30",

pages = "1517--1531",

journal = "Experimental Dermatology",

issn = "0906-6705",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

Alenius, H, Sinkko, H, Moitinho-Silva, L, Rodriguez, E, Broderick, C, Alexander, H, Reiger, M, Hjelmsø, MH, Fyhrquist, N, Olah, P, Bryce, P, Smith, C, Koning, F, Eyerich, K, Greco, D, van den Bogaard, EH, Neumann, AU, Traidl-Hoffmann, C, Homey, B, Flohr, C, Bønnelykke, K, Stokholm, J & Weidinger, S 2021, 'The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases', Experimental Dermatology, vol. 30, no. 10, pp. 1517-1531. https://doi.org/10.1111/exd.14446

TY - JOUR

T1 - The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

AU - Alenius, Harri

AU - Sinkko, Hanna

AU - Moitinho-Silva, Lucas

AU - Rodriguez, Elke

AU - Broderick, Conor

AU - Alexander, Helen

AU - Reiger, Matthias

AU - Hjelmsø, Mathis Hjort

AU - Fyhrquist, Nanna

AU - Olah, Peter

AU - Bryce, Paul

AU - Smith, Catherine

AU - Koning, Frits

AU - Eyerich, Kilian

AU - Greco, Dario

AU - van den Bogaard, Ellen H.

AU - Neumann, Avidan U.

AU - Traidl-Hoffmann, Claudia

AU - Homey, Bernhard

AU - Flohr, Carsten

AU - Bønnelykke, Klaus

AU - Stokholm, Jakob

AU - Weidinger, Stephan

PY - 2021/10

Y1 - 2021/10

N2 - The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.

AB - The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.

KW - atopic dermatitis

KW - biomarkers

KW - microbiome

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85113749271&partnerID=8YFLogxK

U2 - 10.1111/exd.14446

DO - 10.1111/exd.14446

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 34387406

AN - SCOPUS:85113749271

SN - 0906-6705

VL - 30

SP - 1517

EP - 1531

JO - Experimental Dermatology

JF - Experimental Dermatology

IS - 10

ER -

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this